sirukumab - Articles and news items

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

Phase III study of sirukumab in giant cell arteritis starts

Industry news / 27 November 2015 / Victoria White

Sirukumab is an investigational human anti-IL-6 monoclonal antibody that selectively binds with high affinity to the IL-6 cytokine…

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

Asia-Pacific rheumatoid arthritis treatment market value will reach $7 billion by 2021, says GBI Research

Industry news / 2 June 2015 / Victoria White

The rheumatoid arthritis therapeutics market in the APAC region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021…

GlaxoSmithKline logo

GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis

Industry news, News / 23 August 2012 / GlaxoSmithKline

“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...